Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy

被引:134
作者
Vatta, M
Stetson, SJ
Perez-Verdia, A
Entman, ML
Noon, GP
Torre-Amione, G
Bowles, NE
Towbin, JA
机构
[1] Baylor Coll Med, Dept Pediat, Cardiol Sect, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[5] Baylor Coll Med, Winters Ctr Heart Failure Res, Houston, TX 77030 USA
[6] Baylor Coll Med, Gene & Judy Campbell Lab Cardiac Transplant Res, Houston, TX 77030 USA
[7] Baylor Coll Med, Methodist Hosp, DeBakey Heart Ctr, Houston, TX 77030 USA
关键词
D O I
10.1016/S0140-6736(02)08026-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Mutations that lead to disruption of cytoskeletal proteins have been recorded in patients with familial dilated cardiomyopathy. We postulated that changes in cytoskeletal and sarcolemmal proteins provide a final common pathway for dilation and contractile dysfuncton in dilated cardiomyopathy. In this study, we investigated the integrity of dystrophin in the myocardium of patients with end-stage heart failure due to ischaemic or dilated cardiomyopathy, and the response to treatment with left-ventricular assistance devices (LVAD). Methods We assessed the expression and integrity of dystrophin in myocardial biopsy samples by immunohistochemistry and westem-blot analysis using antibodies against the amino-terminal, carboxyl-terminal, and midrod domains. We took samples from the myocardia of ten controls, ten patients with dilated cardiomyopathy, ten with ischaemic heart disease, and six with dilated cardiomyopathy who underwent placement of a left-ventricular assistance device for progressive refractory heart failure. Findings Immunohistochemical staining identified a disruption to the amino-terminus of dystrophin in 18 of 20 patients with end-stage cardiomyopathy (dilated or ischaemic), whereas staining with antibodies against other domains of dystrophin was normal. Westem-blot analysis confirmed these observations, suggesting that remodelling of dystrophin is a common pathway for dysfunction of failing cardiomyocytes. Furthermore, this disruption was reversible in four patients after LVAD support. Interpretation Dystrophin remodelling is a useful indicator of left-ventricular function in patients with dilated and ischaemic cardiomyopathy. Our results lend support to the hypothesis that changes in cytoskeletal proteins and, in particular, dystrophin might provide a final common pathway for contractile dysfunction in heart failure and these changes might be reversible by reduction of mechanical stress.
引用
收藏
页码:936 / 941
页数:6
相关论文
共 31 条
[1]  
Association TCCotNYH, 1994, NOMENCLATURE CRITERI, P253
[2]   Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy [J].
Badorff, C ;
Lee, GH ;
Lamphear, BJ ;
Martone, ME ;
Campbell, KP ;
Rhoads, RE ;
Knowlton, KU .
NATURE MEDICINE, 1999, 5 (03) :320-326
[3]   ENHANCED DEPOSITION OF PREDOMINANTLY TYPE-I COLLAGEN IN MYOCARDIAL-DISEASE [J].
BISHOP, JE ;
GREENBAUM, R ;
GIBSON, DG ;
YACOUB, M ;
LAURENT, GJ .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1990, 22 (10) :1157-1165
[4]   Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 1Oq21-23 [J].
Bowles, KR ;
Gajarski, R ;
Porter, P ;
Goytia, V ;
Bachinski, L ;
Roberts, R ;
Pignatelli, R ;
Towbin, JA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (06) :1355-1360
[5]   Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support [J].
Bruckner, BA ;
Stetson, SJ ;
Perez-Verdia, A ;
Youker, KA ;
Radovancevic, B ;
Connelly, JH ;
Koerner, MM ;
Entman, ME ;
Frazier, OH ;
Noon, GP ;
Torre-Amione, G .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (04) :457-464
[6]   The dystrophinopathies: An alternative to the structural hypothesis [J].
Carlson, CG .
NEUROBIOLOGY OF DISEASE, 1998, 5 (01) :3-15
[7]   Results with the Novacor assist system and evaluation of long-term assistance [J].
Di Bella, I ;
Pagani, F ;
Banfi, C ;
Ardemagni, E ;
Capo, A ;
Klersy, C ;
Viganò, M .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 18 (01) :112-116
[8]   Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. [J].
Fatkin, D ;
MacRae, C ;
Sasaki, T ;
Wolff, MR ;
Porcu, M ;
Frenneaux, M ;
Atherton, J ;
Vidaillet, HJ ;
Spudich, S ;
De Girolami, U ;
Seidman, JG ;
Seidman, CE ;
Muntoni, F ;
Muehle, G ;
Johnson, W ;
McDonough, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (23) :1715-1724
[9]   γ-Sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin [J].
Hack, AA ;
Ly, CT ;
Jiang, F ;
Clendenin, CJ ;
Sigrist, KS ;
Wollmann, RL ;
McNally, EM .
JOURNAL OF CELL BIOLOGY, 1998, 142 (05) :1279-1287
[10]   Recurrent remodeling after ventricular assistance: Is long-term myocardial recovery attainable? [J].
Helman, DN ;
Maybaum, SW ;
Morales, DLS ;
Williams, MR ;
Beniaminovitz, A ;
Edwards, NM ;
Mancini, DM ;
Oz, MC .
ANNALS OF THORACIC SURGERY, 2000, 70 (04) :1255-1258